Organic & Biomolecular Chemistry

Cite this: Org. Biomol. Chem., 2011, 9, 2715

www.rsc.org/obc

A general approach to high-yielding asymmetric synthesis of chiral 3-alkyl-4-nitromethylchromans *via* cascade Barbas–Michael and acetalization reactions[†]

Dhevalapally B. Ramachary,* M. Shiva Prasad and R. Madhavachary

Received 11th October 2010, Accepted 11th January 2011 DOI: 10.1039/c0ob00861c

A general approach to the high-yielding asymmetric synthesis of chiral 3-alkyl-4-nitromethylchromans as drug intermediates was achieved through cascade Barbas–Michael and acetalization (BMA) reactions on 2-(2-nitrovinyl)phenols with aldehydes in the presence of a catalytic amount of (*R*)-DPPOTMS and PhCO₂H. Herein, we have also demonstrated the application of chiral BMA products in the synthesis of functionalized chromanes and chromenes in very good yields with high optical purity, which are very useful compounds in medicinal chemistry.

Introduction

Chromanes and chromenes are important classes of the benzopyran structural unit found in many natural products and are widely used as drug intermediates and ingredients in pharmaceuticals.¹ Chiral benzopyran represents a privileged structural unit that is available in a range of natural products and drug molecules with vast biological applications. Thus, it is very much urgent to develop sustainable asymmetric strategies to construct optically pure chromans and chromenes.² Interestingly, to the best of our knowledge there is no report on the direct catalytic asymmetric method for the synthesis of chiral 3-alkyl-4-nitromethylchromans. Herein, we are reporting the metal-free approach to the asymmetric synthesis of functionalized 3-alkyl-4-nitromethylchroman-2-ols and 3-alkyl-

School of Chemistry, University of Hyderabad, Hyderabad, -500 046, India. E-mail: ramsc@uohyd.ernet.in; Fax: +91-40-23012460

[†] Electronic supplementary information (ESI) available: Experimental procedures and analytical data (¹H NMR, ¹³C NMR, HRMS and HPLC) for all new compounds. CCDC reference number 795663. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c0ob00861c

4-nitromethylchroman-2-ones *via* cascade "Barbas–Michael and acetalization (*BMA*) reactions".³

Recently Barbas *et al.* discovered the modern technology of amine-catalyzed Michael reactions of ketones/aldehydes with variety of active olefins to provide a variety of Michael adducts in good yields with high enantioselectivity, which has become the "Barbas–Michael reaction".⁴ The advent of this bio-mimetic enamine based technology triggered a burst of activity in the synthesis of a huge variety of chiral pool of 1,4-adducts.⁴

However, the amine-catalyzed Michael reaction of aldehydes 1 with 2-(2-nitrovinyl)phenols 2 was not known and resulting products 5/6 have a wide range of uses in pharmaceutical chemistry (see Scheme 1) and also there is no methodology available to prepare even achiral compounds 5/6.⁵ Herein, we have reported a metalfree technology for the asymmetric synthesis of substituted 3-alkyl-4-nitromethylchroman-2-ols 5/6, 3-alkyl-4-nitromethylchroman-2-ones 7/8 and 2-(3-hydroxy-2-alkyl-1-nitromethylpropyl)phenols 9/10 by using organocatalytic BMA, oxidation and reduction reactions from easily available aldehydes 1, 2-(2-nitrovinyl)phenols 2, amines 3, acids 4, PCC or IBX and NaBH₄ (Scheme 1).

In a continuation of our investigation for new reactive species for the development of green asymmetric cascade reactions,⁶



Scheme 1 Direct organocatalytic asymmetric cascade BMA reactions.

Table 1 Reaction optimization for the cascade BMA reaction of 1a and 2a

	A CO ₂ H 3a	Catalyst 3 Co-catalyst 4 Solvent (0.25 M) 1a Ta Sb Solvent (0.25 M) RT	$\begin{array}{c} O_2 N \\ \hline O_2 N \\ \hline$	PCC (3 equiv.) NaOAc (3 equiv.) DCM (0.1 M) RT, 1-2 h Ph OTMS Ph H H H H H H H H H H H H H			
Entry	Catalyst 3/4 (20/20 mol%)	Solvent (0.25 M)	Time (h)	Product yield (%) ^a		ee (%) ^b	de (%) ^b
				5aa	7aa	7aa	7aa
1	3a	DMSO	8	52	50	31	90
2	3b /PhCO ₂ H 4a	DCM	4	70	50	46	63
3	3c	Hexane	10	76	63	97	88
4	3c/4a	Hexane	18	93	63	99	95
5	3c/4a	Et_2O	4	65	50	87	66
6	3c/4a	Toluene	4	60	50	96.7	81
7	$3c/MeCO_2H 4b$	DCM	2	92	50	97	69
8	3c/Ph ₂ CHCO ₂ H 4c	DCM	2	80	40	97.8	66
9	3c/4a	DCM	1	89	65	98	82
10	3d/4a	$C_6H_5CH_3$	2	87	50	96.6	76
11	3d/4a	DCM	2	87	50	98	79
12	3e/4a	DCM	1	96	60	-99.9	<i>95</i>
13 ^c	3e/4a	DCM	0.5	95	70	-99.9	<i>93</i>
14	3f/4a	DCM	24	72	50	-87	43
15	3f/4a	$C_6H_5CH_3$	36	70	50	-85	32

^{*a*} Yield refers to the column-purified product. ^{*b*} ee and de determined by CSP HPLC analysis. ^{*c*} Oxidation was carried out with 1.5 equiv. of IBX in CHCl₃ at 65 °C for 15–24 h.

we decided to explore the 2-(2-nitrovinyl)phenols **2** as an active olefin in an amine-catalyzed BMA reaction with aldehydes **1**. We thought that the reaction of 2-(2-nitrovinyl)phenols **2** with *in situ*-generated enamine from aldehydes **1** would lead to 3-(2-hydroxyphenyl)-2-alkyl-4-nitrobutyraldehydes. However, Michael adducts were not detected and instead it has shown the completely cyclized lactol product of 3-alkyl-4-nitromethylchroman-2-ols **5**/**6** under the standard reaction conditions. This interesting result represents a novel tool for the preparation of chiral lactols **5**/**6** and a new reactivity for amine catalysts. Herein, we report our findings regarding these new cascade asymmetric reactions.

Results and discussion

Direct amine-catalyzed asymmetric cascade BMA reaction of propionaldehyde with 2-methoxy-6-(2-nitrovinyl)phenol: reaction optimization

For the optimization of designed BMA reaction, we screened a number of organocatalysts for the reaction of 2-methoxy-6-(2-nitrovinyl)phenol **2a** with 10 equiv. of propionaldehyde **1a** and some important results are shown in Table 1. Interestingly, reaction of **2a** with 10 equiv. of **1a** in DMSO under 20 mol% of L-proline **3a**-catalysis furnished the 1 : 1 ratio of *cis*-lactol/*trans*-lactol of major product *syn*-**5aa** in 52% yield with 31% ee and 90% de along with minor isomer *anti*-**6aa** (see Scheme 1 and Table 1, entry 1). For the clear understanding of diastereoselectivity between **5aa** and **6aa**;

and also for the clear HPLC separation, we transformed the crude product 5aa/6aa into two easily separable products cis-7aa and trans-8aa with 50% yield via PCC oxidation in DCM at 25 °C for 1-2 h (see Table 1). In a further optimization, reaction of 1a and 2a in DCM under 20 mol% of diamine/PhCO₂H 3b/4a-catalysis followed by PCC oxidation furnished the major product cis-(-)-7aa in 50% yield with only 46% ee and 63% de (Table 1, entry 2). Interestingly, reaction of 1a with 2a in hexane under 20 mol% of (S)- α , α -diphenylprolinol trimethylsilyl ether (L-DPPOTMS) 3c-catalysis at 25 °C for 10 h furnished the lactols 5aa/6aa in 76% yield, which on further oxidation with PCC furnished the major product cis-(-)-7aa in 63% yield with 97% ee and 88% de (Table 1, entry 3). The same reaction under 20 mol% of L-DPPOTMS/PhCO₂H 3c/4a-catalysis in hexane for 18 h furnished the lactols 5aa/6aa in 93% yield, which on further PCC oxidation furnished the major product cis-(-)-7aa in 63% yield with 99% ee and 95% de (Table 1, entry 4).

To further improve the asymmetric BMA reaction, especially for decreasing the reaction time to <1 h and increasing the ee/de to >99.9%, we tested the BMA reaction of **1a** and **2a** catalyzed by **3c** and **3d** with different acids **4a–c** as co-catalysts in various solvents. But none of these results are superior compared to entry 4 except in decreasing the reaction time (Table 1, entries 5–11). Interestingly, cascade BMA reaction of **1a** with **2a** in DCM under 20 mol% of D-DPPOTMS/PhCO₂H **3e/4a**-catalysis at 25 °C for 1 h furnished the lactols **5aa/6aa** in 96% yield, which on further oxidation with PCC furnished the major product *cis*-(+)-**7aa** in



^{*a*} Reactions were carried out in DCM (0.25 M) with 10 equiv. of **1a** or 1.5 equiv. of **1b–f** relative to the **2a–j** (0.5 mmol) in the presence of 20 mol% of catalyst **3e/4a**. ^{*b*} Yield refers to the column-purified product. ^{*c*} ee and de were determined by CSP HPLC analysis (see SI⁺).

60% yield with 99.9% ee and 95% de (Table 1, entry 12). The yield of the oxidation product *cis*-(+)-7**aa** was improved by treating crude **5aa/6aa** with 1.5 equiv. of IBX in CHCl₃ at 65 °C for 15-24 h as shown in Table 1, entry 13. After successful results with chiral D-DPPOTMS **3e** as a catalyst, we were interested in screening alkaloid based primary amines like 9-amino-9-deoxyepiquinine **3f** as the catalyst for the BMA reaction to monitor the outcome of

selectivity (Table 1, entries 14–15).⁷ Interestingly, BMA reaction of **2a** with 10 equiv. of **1a** under 20 mol% of **3f/4a**-catalysis in DCM or toluene for 24/36 h, followed by oxidation, furnished the major product *cis*-(+)-**7aa** in 50% yield with only 87/85% ee and 43/32% de, respectively (Table 1, entries 14–15). Finally we envisioned the optimized condition to be 25 °C in DCM under 20 mol% of D-DPPOTMS/PhCO₂H **3e/4a**-catalysis followed by IBX



Scheme 2 Synthesis of chromanes with three contiguous stereocenters.

oxidation to furnish the highly substituted cascade BMA product *cis*-(+)-**7aa** in 70% yield with 99.9% ee and 93–95% de (Table 1, entry 13). Structure and absolute stereochemistry of cascade BMA products **5aa/6aa** and **7aa/8aa** was confirmed by NMR analysis and also finally confirmed by X-ray structure analysis on (-)-**7aa** as shown in Figure S1 (see Supporting Information†).⁸

Diversity-oriented synthesis of chiral BMA products 5-9

With the optimized reaction conditions in hand, the scope of the amine-catalyzed asymmetric cascade BMA reactions was investigated.⁹ A series of substituted 2-(2-nitrovinyl)phenols 2a-j were reacted with 10 equiv. of propionaldehyde 1a catalyzed by 20 mol% of 3e/4a at 25 °C in DCM, for 0.5-4 h, to furnish chiral cascade BMA products 5aa-aj with very good yields, ee's and de's, which on further oxidation with IBX or reduction with NaBH₄, furnished the products 7 and 9, respectively (Table 2).¹⁰ The chiral cascade products 5aa-aj, 7aa-aj and 9aa-aj were obtained as major isomers with excellent yields, ee's and de's. Without showing much of electronic factors, neutral, electron-withdrawing and electron-donating substituted 2-(2-nitrovinyl)phenols 2a-j generated expected products 5aa-aj, 7aa-aj and 9aa-aj with excellent yields, ee's and de's (see Table 2). Fascinatingly, reaction of 2-(2-nitrovinyl)phenol 2b with propionaldehyde 1a under 3e/4acatalysis furnished the cis-lactol (+)-5ab as the major product in 90% yield, which on further reduction with NaBH₄ furnished the diol (+)-9ab as the major product with >95% yield with 89% ee and >99% de (Table 2, entry 2). In a similar manner, 2-methoxy-6-(2-nitrovinyl)phenol 2a was reacted with a series of aldehydes 1b-f, catalyzed by 20 mol% of 3e/4a at 25 °C in DCM for 6-9 h, to furnish chiral cascade BMA products 5ba-fa with very good yields, ee's and de's, which on further oxidation with IBX or reduction with NaBH₄, furnished the products 7ba-fa and 9ba-fa, respectively (Table 2). Structure and stereochemistry of BMA products 5aa-fa, 7aa-fa and 9aa-fa was confirmed by NMR analysis.

Applications of chiral BMA products

Synthesis of functionalized chiral chromanes and chromenes based on the BMA platform. With synthetic and pharmaceutical applications in mind, we decided to explore the utilization of *cis*- lactols 5 in the synthesis of functionalized chiral chromanes and chromenes via acid-catalysis as shown in Schemes 2-4. Reaction of pure lactol (+)-5ab with 20 mol% of p-TSA in polar protic solvent of MeOH (a) at 0 °C for 0.5 h, and 25 °C for 3 h, furnished the cyclized 2-methoxy-3-methyl-4-nitromethylchromane trans-(-)-5aba in 63% yield with 98% ee and cis-(+)-5aba in 25% yield with 99% ee as shown in Scheme 2. In a similar manner, reaction of (+)-5ad with 40 mol% of p-TSA in MeOH (a) at 0 °C for 0.5 h, and 25 °C for 5 h, furnished the cyclized 6-chloro-2-methoxy-3-methyl-4-nitromethylchromane trans-(-)-5ada in 65% yield with 81% ee and cis-(+)-5ada in 21% yield with 90% ee as shown in Scheme 2. Interestingly, isomers of chiral chromanes cis-5aba-ada/trans-5aba-ada containing three contiguous stereocenters are easily separated from simple column chromatography and also diversityoriented synthesis of these chiral chromanes could be obtained from sequential one-pot operation for synthetic applications.

Interestingly, a similar type cyclization reaction on *cis*-lactol (+)-5aa with 5-10 mol% of p-TSA in nonpolar aprotic solvent of toluene at 110 °C for 1 h furnished the selectively cyclized 8methoxy-3-methyl-4-nitromethyl-4H-chromene (-)-11aa in 86% yield with 99% ee as shown in Scheme 3. Hydrogenation of (-)-11aa with 10% Pd/C in methanol at 25 °C for 4 h followed by baseinduced Boc₂O protection furnished the partially hydrogenated amine (-)-12aa in 75% yield with 81% ee. The same hydrogenation on (-)-11aa for a longer reaction time (14 h) followed by baseinduced Boc₂O protection furnished the completely hydrogenated amine (+)-13aa in 75% yield with <5% de and each 93% ee as shown in Scheme 3. In a similar manner, reaction of *cis*-lactol (+)-**5ab** with 10 mol% of *p*-TSA in toluene at 110 °C for 1 h furnished the selectively cyclized 3-methyl-4-nitromethyl-4H-chromene (-)-11ab in 90% yield with 94% ee as shown in Scheme 3. Double hydrogenation of (-)-11ab with 10% Pd/C in methanol at 25 °C for 8 h followed by base-induced Boc₂O protection furnished the completely hydrogenated amine (+)-13ab in 85% yield with <5%de and 94% ee as shown in Scheme 3.

As illustrated in Scheme 4, highly functionalized chromane acetates containing three contiguous stereocenters could be produced through cascade Wittig reaction followed by intramolecular oxa-Michael addition (W/OM) on the BMA compound of (+)-**5aa** with Ph₃P=CHCO₂Me. The two isomers *cis*-**14aa** and *trans*-**14aa** were furnished in 26% yield with 99% ee and 28% yield with 99% ee, respectively, as shown in Scheme 4.



Scheme 4 Synthesis of chiral chromane acetates via cascade W/OM reactions on BMA products.

Structure and stereochemistry of cascade W/OM products **14aa** was confirmed by NMR analysis and also finally confirmed by ¹H–¹H COSY analysis on (+)-*cis*-**14aa** (see Supporting Information[†]). Functionalized chiral methyl chromane acetates **14** could be suitable starting materials for the synthesis of vitamin E analogues.

Compounds (–)-**5ada**, (–)-**12aa** and (+)-**13aa** are drug-like molecules; these types of molecules are used for the treatment of potent anti-ischemic property, anti-hypertensives, spasmolytics for blood vessels and also as potassium channel blockers, which emphasizes the value of this BMA approach to pharmaceuticals.¹ In addition, the presently discovered cascade BMA technology will be suitable to develop the substituted benzopyran structural unit, which is found in many natural products and designed drug molecules.^{2a}

Mechanistic insights

Although further studies are needed to firmly elucidate the mechanism of the phenol group involvement in an asymmetric BMA reaction through 3e/4a- or 3f/4a-catalysis, the reaction most likely proceeds *via* an enamine mechanism (see Fig. 1). In the case of the addition of aldehydes 1a-f to substituted 2-(2-nitrovinyl)phenols 2a-j *via* D-DPPOTMS/PhCO₂H 3e/4a-catalysis, we can rationalize the observed stereochemistries through a favoured transition state where the less hindered *re*-face of 2a-j approaches the *re*-face of enamine as shown in TS-1. In the case of 3f/4a-catalysis, the observed similar enantioselectivity and poor diastereoselectivity may be explained by model TS-2, in which there are favourable electrostatic interactions between the partially positive nitrogen of the quinine and the partially negative nitro group, and also between the partially positive phenolic OH and the partially negative quinine OMe in the transition state (Fig. 1). The observed stereochemistries of the products **5** could be explained by approach of the **2a–j** from the less hindered *re*-face to the *re*- or *si*-face of enamine as shown in **TS-2**.

Conclusions

In summary, we have developed the D-DPPOTMS/PhCO₂H 3e/4a-catalyzed asymmetric cascade BMA reaction of aldehydes with 2-(2-nitrovinyl)phenols at ambient conditions. The cascade asymmetric reaction proceeds in very good yields with high selectivity using 3e/4a as the catalyst. Furthermore, we have demonstrated the application of chiral lactol products 5 in the synthesis of functionalized chromanes and chromenes, which are very useful compounds in medicinal chemistry. Further work is in progress to utilize chiral lactols 5 as intermediates for the bioactive molecules synthesis.

Experimental

General methods. The ¹H NMR and ¹³C NMR spectra were recorded at 400 MHz and 100 MHz, respectively. The chemical shifts are reported in ppm downfield to TMS ($\delta = 0$) for ¹H NMR and relative to the central CDCl₃ resonance ($\delta = 77.0$) for ¹³C NMR. In the¹³C NMR spectra, the nature of the carbons



Fig. 1 Proposed transition states for the cascade BMA reactions.

 $(C, CH, CH_2 \text{ or } CH_3)$ was determined by recording the DEPT-135 experiment, and is given in parentheses. The coupling constants J are given in Hz. Column chromatography was performed using Acme's silica gel (particle size 0.063-0.200 mm). High-resolution mass spectra were recorded on micromass ESI-TOF MS. GC-MS mass spectrometry was performed on Shimadzu GCMS-QP2010 mass spectrometer. Elemental analyses were recorded on a Thermo Finnigan Flash EA 1112 analyzer. LC-MS mass spectra were recorded on either a VG7070H mass spectrometer using EI technique or a Shimadzu-LCMS-2010A mass spectrometer. IR spectra were recorded on JASCO FT/IR-5300 and Thermo Nicolet FT/IR-5700. The X-ray diffraction measurements were carried out at 298 K on an automated Enraf-Nonious MACH 3 diffractometer using graphite monochromated, Mo-K α (λ = 0.71073 Å) radiation with CAD4 software, or the X-ray intensity data were measured at 298 K on a Bruker SMART APEX CCD area detector system equipped with a graphite monochromator and a Mo-K α fine-focus sealed tube ($\lambda = 0.71073$ Å). For thinlayer chromatography (TLC), silica gel plates Merck 60 F254 were used and compounds were visualized by irradiation with UV light and/or by treatment with a solution of *p*-anisaldehyde (23 mL), conc. H₂SO₄ (35 mL), acetic acid (10 mL), and ethanol (900 mL) followed by heating.

Materials. All solvents and commercially available chemicals were used as received.

General experimental procedures for the cascade BMA reactions

General procedure for amine-catalyzed asymmetric cascade BMA reaction of aldehydes 1 with 2-(2-nitrovinyl)phenols 2. In an ordinary glass vial equipped with a magnetic stirring bar, to a mixture of D-DPPOTMS 3e (0.1 mmol) and PhCO₂H 4a (0.1 mmol) in DCM (2.0 mL), was added propionaldehyde 1a (5.0 mmol, 10 equiv.) or aldehydes 1b–f (0.75 mmol, 1.5 equiv.) and 2-(2-nitrovinyl)phenols 2a–j (0.5 mmol). After stirring the reaction mixture was worked up with aqueous NH₄Cl solution and the aqueous layer was extracted with ethyl acetate (3×10 mL). The combined organic layers were dried (Na₂SO₄), filtered and concentrated. Pure chiral products 5/6 were obtained by column chromatography (silica gel, mixture of hexane–ethyl acetate).

General procedure for the oxidation of cascade BMA products with IBX. In an oven dried round bottom flask, to the lactol 5/6 (0.3 mmol), added dry CHCl₃ (3.0 mL), and IBX (0.45 mmol,

1.5 equiv.). After stirring the reaction mixture at 65 °C for 15–24 h, it was brought to 25 °C and the crude reaction mixture was passed through a pad of celite and concentrated to dryness. Pure chiral products 7 were obtained by column chromatography (silica gel, mixture of hexane–ethyl acetate).

General procedure for the reduction of cascade BMA products. In an oven dried round bottom flask, to the lactol 5/6 (0.3 mmol), dry MeOH (3.0 mL), and NaBH₄ (0.45 mmol, 1.5 equiv.) was added. After stirring the reaction mixture at 0 °C for 0.5 h, it was brought to 25 °C and the crude reaction mixture was worked up with aqueous NH₄Cl solution. The aqueous layer was extracted with dichloromethane (3 × 10 mL). The combined organic layers were dried (Na₂SO₄), filtered and concentrated. Pure chiral products **9** were obtained by column chromatography (silica gel, mixture of hexane–ethyl acetate).

Brønsted acid-catalyzed hydrolysis of cascade BMA products. In an oven dried round bottom flask, to the lactol 5/6 (0.3 mmol), dry toluene (3.0 mL), and *p*-TSA·H₂O (3.5 mg, 10 mol%) was added. After heating the reaction mixture to 110 °C for 1 h, it was brought to 25 °C and the crude reaction mixture was worked up with aqueous NaHCO₃ solution. The aqueous layer was extracted with dichloromethane (3×10 mL). The combined organic layers were dried (Na₂SO₄), filtered and concentrated. Pure chiral products **11** were obtained by column chromatography (silica gel, mixture of hexane–ethyl acetate).

Hydrogenation followed by protection of nitro products. In an oven dried round bottom flask, activated (10%) Pd/C (7 mg, 10 mol%) was taken with compound (–)-11aa (0.3 mmol), dissolved in dry MeOH (3.0 mL) and stirred under H₂ atmosphere at 25 °C for 4 or 14 h. The reaction mixture was passed through a pad of celite and concentrated to dryness. The crude mixture was taken in a dry oven dried round bottom flask in dry DCM (3.0 mL) and dry triethylamine (60 μ L, 0.4 mmol) and di-*tert*-butyl carbonate (86 mg, 0.4 mmol) was successively at 0 °C. The resulting mixture was stirred at 25 °C for 2 h and then worked up with aqueous NH₄Cl. The aqueous layer was extracted with ethyl acetate (3 × 10 mL). The combined organic layers were dried (Na₂SO₄), filtered and concentrated. Pure product (–)-12aa or (+)-13aa was obtained by column chromatography (silica gel, mixture of hexane–ethyl acetate).

Acknowledgements

This work was made possible by a grant from the Department of Science and Technology (DST), New Delhi [Grant No.: DST/SR/S1/OC-65/2008]. MSP and RM thank Council of Scientific and Industrial Research (CSIR), New Delhi for their research fellowship. We thank Dr P. Raghavaiah for his help in X-ray structural analysis.

References

- 1 (a) R. C. Neugebauer, U. Uchiechowska, R. Meier, H. Hruby, V. Valkov, E. Verdin, W. Sippl and M. Jung, J. Med. Chem., 2008, 51, 1203-1213; (b) J. Posakony, M. Hirao, S. Stevens, J. A. Simon and A. Bedalov, J. Med. Chem., 2004, 47, 2635-2644; (c) S. R. Trenor, A. R. Shultz, B. J. Love and T. E. Long, Chem. Rev., 2004, 104, 3059-3077; (d) S. A. Buckner, I. Milicic, A. Daza, R. Davis-Taber, V. E. S. Scott, J. P. Sullivan and J. D. Brioni, Eur. J. Pharmacol., 2000, 400, 287-295; (e) A. Coi, A. M. Bianucci, V. Calderone, L. Testai, M. Digiacomo, S. Rapposelli and A. Balsamo, Bioorg. Med. Chem., 2009, 17, 5565-5571; (f) M. C. Breschi, V. Calderone, A. Martelli, F. Minutolo, S. Rapposelli, L. Testai, F. Tonelli and A. Balsamo, J. Med. Chem., 2006, 49, 7600-7602; (g) A. Widdig, H. J. Kabbe, A. Knorr, U. Benz, Ger. Offen, 1984, 77, DE 3300004 A1 19840712 [Chem. Abstr., 1984, 102, 6203] (patent written in German); (h) S. Khelili, X. Florence, M. Bouhadja, S. Abdelaziz, N. Mechouch, Y. Mohamed, P. D. Tullio, P. Lebrun and B. Pirotte, Bioorg. Med. Chem., 2008, 16, 6124-6130; (i) R. Grandel, W. M. Braje, A. Haupt,S. C. Turner, U. Lange, K. Drescher,L. Unger, D. Plata, PCT Int. Appl., 2007, 113, WO 2007118899 A1 20071025, [Chem. Abstr., 2007, 147, 486320] (patent written in English).
- 2 (a) K. C. Nicolaou, J. A. Pfefferkorn, A. J. Roecker, G. Q. Cao, S. Barluenga and H. J. Mitchell, *J. Am. Chem. Soc.*, 2000, **122**, 9939–9953 and references therein; (b) B. Lesch and S. Braese, *Angew. Chem., Int. Ed.*, 2004, **43**, 115–118; (c) L. F. Tietze, D. A. Spiegl, F. Stecker, J. Major, C. Raith and C. Große, *Chem.–Eur. J.*, 2008, **14**, 8956–8963.
- 3 For recent papers on sequential Michael and lactonization reactions, see: (a) S. Belot, K. A. Vogt, C. Besnard, N. Krause and A. Alexakis, Angew. Chem., Int. Ed., 2009, 48, 8923–8926; (b) M. Rueping, E. Merino and E. Sugiono, Adv. Synth. Catal., 2008, 350, 2127–2131; (c) P. Buchgraber, T. N. Snaddon, C. Wirtz, R. Mynott, R. Goddard and A. Fürstner, Angew. Chem., Int. Ed., 2008, 47, 8450–8454. While our manuscript was in the reviewing process, a related chroman synthesis was reported, see: (d) B.-C. Hong, P. Kotame and J.-H. Liao, Org. Biomol. Chem., 2011, 9, 382–386; (e) D. Enders, C. Wang, X. Yang and G. Raabe, Adv. Synth. Catal., 2010, 352, 2869–2874; (f) D. Lu, Y. Li and Y. Gong, J. Org. Chem., 2010, 75, 6900–6907.
- 4 For selected recent papers on enamine-based Michael reaction of carbonyl compounds with β -nitrostyrenes, see: (a) K. Sakthivel, W.

Notz, T. Bui and C. F. Barbas III, J. Am. Chem. Soc., 2001, 123, 5260-5267; (b) J. M. Betancort, K. Sakthivel, R. Thayumanavan and C. F. Barbas III, Tetrahedron Lett., 2001, 42, 4441-4444; (c) J. M. Betancort and C. F. Barbas III, Org. Lett., 2001, 3, 3737-3740; (d) B. List, P. Pojarliev and H. J. Martin, Org. Lett., 2001, 3, 2423-2425; (e) N. Mase, R. Thayumanavan, F. Tanaka and C. F. Barbas III, Org. Lett., 2004, 6, 2527–2530; (f) J. M. Betancort, K. Sakthivel, R. Thayumanavan, F. Tanaka and C. F. Barbas III, Synthesis, 2004, 1509-1521; (g) A. J. A. Cobb, D. A. Longbottom, D. M. Shaw and S. V. Ley, Chem. Commun., 2004, 1808-1809; (h) Y. Hayashi, H. Gotoh, T. Hayashi and M. Shoji, Angew. Chem., Int. Ed., 2005, 44, 4212-4215; (i) D. Enders, M. R. M. Hüttl, C. Grondal and G. Raabe, Nature, 2006, 441, 861-863; (j) P. García-García, A. Ladépêche, R. Halder and B. List, Angew. Chem., Int. Ed., 2008, 47, 4719-4721; (k) P. Dinér, A. Kjærsgaard, M. A. Lie and K. A. Jørgensen, Chem.-Eur. J., 2008, 14, 122-127; (1) X. Zhu, F. Tanaka, R. A. Lerner, C. F. Barbas III and I. A. Wilson, J. Am. Chem. Soc., 2009, 131, 18206-18207; (m) H. Uehara and C. F. Barbas III, Angew. Chem., Int. Ed., 2009, 48, 9848-9852; (n) V. Maya and V. K. Singh, Org. Lett., 2007, 9, 1117-1119; (o) J. N. Moorthy and S. Saha, Eur. J. Org. Chem., 2010, 6359-6365.

- 5 For organocatalytic asymmetric sequential Michael-acetalization (SMA) reactions of acetone with 2-(2-nitrovinyl)phenols and methanol, see: D. B. Ramachary and R. Sakthidevi, *Org. Biomol. Chem.*, 2010, **8**, 4259–4265.
- 6 For selected recent papers on asymmetric cascade reactions from our group, see: (a) D. B. Ramachary and M. Kishor, J. Org. Chem., 2007, 72, 5056–5068; (b) D. B. Ramachary and R. Sakthidevi, Org. Biomol. Chem., 2008, 6, 2488–2492; (c) D. B. Ramachary and M. Kishor, Org. Biomol. Chem., 2008, 6, 4176–4187; (d) D. B. Ramachary and R. Sakthidevi, Chem.-Eur. J., 2009, 15, 4516–4522; (e) D. B. Ramachary and Y. V. Reddy, J. Org. Chem., 2010, 75, 74–85.
- 7 For selected recent papers on 9-amino-9-deoxyepiquinine 3f-catalyzed asymmetric reactions, see: (a) C. M. Reisinger, X. Wang and B. List, Angew. Chem., Int. Ed., 2008, 47, 8112–8115; (b) M. W. Paixao, N. Holub, C. Vila, M. Nielsen and K. A. Jørgensen, Angew. Chem., Int. Ed., 2009, 48, 7338–7342; (c) D. B. Ramachary and M. Kishor, Org. Biomol. Chem., 2010, 8, 2859–2867 and references therein.
- 8 CCDC-795663 for (-)-7aa contains the supplementary crystallographic data for this paper. This data can be obtained free of charge *via* http://www.ccdc.cam.ac.uk/conts/retrieving.html or from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB21EZ, UK; fax: (+44)1223-336-033; or mailto:deposit@ccdc.cam.ac.uk. See supporting information for crystal structure†.
- 9 For organocatalytic synthesis of substituted 2-(2-nitrovinyl)phenols 2aj, see: D. B. Ramachary and R. Sakthidevi, Org. Biomol. Chem., 2010, 8, 4259–4265.
- 10 For organocatalytic high-yielding synthesis of racemic products **5aa fa**, **7aa–fa** and **9aa–fa** from **1a–f** and **2a–j** through DL-proline-catalysis, see Table S1 in Supporting Information-I.† For, the *ee* and *de*'s of minor compounds **6/8/10**, see Supporting Information-I and II†.